中华灾害救援医学2017，Vol.5Issue(2)：101-105,5.DOI:10.13919/j.issn.2095-6274.2017.02.011
急性冠脉综合征患者经皮冠状动脉介入术中比伐卢定的研究进展
Bivalirudin in treatment of acute coronary syndrome with percutaneous coronary intervention:a brief review
伍雪峰 1金至赓 1赖斌 1刘惠亮1
作者信息
- 1. 100039 北京，武警总医院心血管内科
- 折叠
摘要
Abstract
Bivalirudin is a direct antithrombin inhibitor, which has been proven by large clinical studies and basic researches that could replace unfractionated heparin (UFH) plus platelet glycoproteinⅡb/Ⅲa receptor antagonist in the antithrombotic therapy of acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention.This article reviews the advance in research of bivalirudin in treatment of ACS with percutaneous coronary intervention (PCI).关键词
比伐卢定/肝素/急性冠脉综合征/经皮冠状动脉介入术Key words
bivalirudin/heparin/acute coronary syndrome/percutaneous coronary intervention分类
医药卫生引用本文复制引用
伍雪峰,金至赓,赖斌,刘惠亮..急性冠脉综合征患者经皮冠状动脉介入术中比伐卢定的研究进展[J].中华灾害救援医学,2017,5(2):101-105,5.
